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Carbohydrate-sulfotransferaseGeneralized peeling skin syndrome (PSS) is an autosomal recessive genodermatosis characterized by
lifelong, continuous shedding of the upper epidermis. Using whole-genome homozygozity mapping
and whole-exome sequencing, we identiﬁed a novel homozygous missense mutation (c.229C>T,
R77W) within the CHST8 gene, in a large consanguineous family with non-inﬂammatory PSS type A.
CHST8 encodes a Golgi transmembrane N-acetylgalactosamine-4-O-sulfotransferase (GalNAc4-ST1),
which we show by immunoﬂuorescence staining to be expressed throughout normal epidermis. A col-
orimetric assay for total sulfated glycosaminoglycan (GAG) quantiﬁcation, comparing human keratino-
cytes (CCD1106 KERTr) expressing wild type and mutant recombinant GalNAc4-ST1, revealed
decreased levels of total sulfated GAGs in cells expressing mutant GalNAc4-ST1, suggesting loss of
function. Western blotting revealed lower expression levels of mutant recombinant GalNAc4-ST1 com-
pared to wild type, suggesting that accelerated degradation may result in loss of function, leading to
PSS type A. This is the ﬁrst report describing a mutation as the cause of PSS type A.
© 2012 Elsevier Inc. All rights reserved.1. Introduction
Peeling skin syndrome (PSS) is a group of rare autosomal recessive
genodermatoses that can be divided into two main types: Acral PSS
(APSS; OMIM 609796) and generalized PSS (OMIM 270300). A third
form of facial peeling syndrome has also been reported [1]. General-
ized PSS can be further divided into the non-inﬂammatory (type A)
and the inﬂammatory (type B) forms [2].
PSS is described clinically and characterized histologically by
asymptomatic lifelong and continuous shedding of the stratum cor-
neum of the epidermis, due to the separation between keratinocyte
layers at a subcorneal or intracorneal level [3,4]. This condition can
present at birth or appear in early childhood [2,5]. PSS can be distin-
guished histologically from the different types of epidermolysisO-sulfotransferase; PSS, peeling
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rights reserved.bullosa, in which blistering occurs within or below the basal layer of
the epidermis [6,7], in contrast to the blistering high in the epidermis,
at the stratum granulosum–corneum junction, seen in PSS.
APSS (localized form) involves the palmar, plantar and dorsal sur-
faces of hands and feet and is caused by mutations in the tranglutami-
nase 5 gene (TGM5) [8]. TGM5 is involved in cross-linking structural
proteins for the formation of the corniﬁed envelope, by catalyzing
the formation of γ-glutamyl-ε-lysine isopeptide bonds between
differentiation-speciﬁc proteins expressed mainly in corneocytes, in-
cluding loricrin, involucrin and small proline-rich proteins [8].
Recently, it was found that recessive mutations in the corneo-
desmosin gene (CDSN) underlie PSS type B [9,10]. CDSN is a
component of corneodesmosomes at the transition from the
granular to corniﬁed layers, and is involved in the late stages of
epidermal differentiation, having a critical role in reinforcing
cell–cell adhesion and maintaining the integrity of the stratum
corneum. Patients with PSS type B share several clinical features
with Netherton syndrome (NS, MIM 256500), presenting at
birth with ichthyosiform erythroderma and white superﬁcial ex-
foliation with recurrent ﬂares of erythema, scaling and pruritis
and increased predisposition to atopic diseases [9]. Interestingly,
dominant mutations in CDSN are also associated with localized
hypotrichosis simplex (MIM 146520) [11]. Homozygous loss-of-
function mutations (a splice-site and a nonsense mutation) in
the gene for protease inhibitor cystatin A (CSTA) have been
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ichthyosis. Patients with this condition present with dry, scaly
skin over most of the body with coarse peeling of nonerythema-
tous skin on the palms and soles. In contrast to PSS syndrome,
electron microscopy of skin biopsies from affected individualsFig. 1. Autozygozity mapping and whole-exome sequencing identify homozygous missense
lotype analysis in a large consanguineous family with PSS type A. Arrows indicate the key re
peeling of the skin. (C) Autozygozity mapping using the Affymetrix 10 K genotyping chip. A
Sanger sequencing of genomic DNA from patients 1–18 conﬁrms presence of a homozygous
trol, heterozygous carrier and homozygous affected individuals are shown (red star showswith exfoliative ichthyosis revealed that the level of detachment
occurs in the basal and lower suprabasal layers [12].
We undertook this study to identify the gene responsible for non-
inﬂammatory PSS type A, with the aim of deﬁning a new genetic de-
terminant of epidermal differentiation.mutation in CHST8 in a Pakistani family with PSS non-inﬂammatory type A. (A) Hap-
combination events. (B) Clinical phenotype of an affected individual reveals superﬁcial
maximum LOD score of 10.9 was obtained for a 23 Mb region on chromosome 19. (D)
c.229C>T mutation in affected individuals. Representative electropherograms for con-
mutated nucleotide).
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2.1. Clinical ﬁndings
We studied a large consanguineous family from Pakistan showing
features of non-inﬂammatory PSS, segregating as a recessive trait. Af-
fected individuals reported symptoms starting during the second half
of the ﬁrst decade of life, consisting of generalized white scaling, most
prominent over the upper and lower extremities (Fig. 1B), with pain-
less and easy removal of the skin (Video S1). Moreover, they reported
irritation when in contact with water, dust and sand. There was no
history of erythema, pruritis or atopy and their hair was normal.
2.2. SNP genomic mapping and microsatellite linkage analysis
We undertook a genome-wide scan using DNA from ten family
members on the low density Affymetrix 10K SNP array and identiﬁed
a region of excess homozygosity shared among affected individuals
on chromosome 19 (23 Mb), with a lod score of 10.9 (Fig. 1C). Micro-
satellite markers spanning the region of autozygosity were then used
to genotype all family members (Fig. 1A). Key recombination events
were detected between markers D19S414 and D19S416, and
D19S903 and D19S412 in the affected number 10 (Fig. 1A), which
allowed the interval of linkage to be narrowed to 16 Mb ﬂanked by
markers D19S414 and D19S412. This region contained more than
one hundred candidate genes.
2.3. Mutation detection and analysis
Because of our well-deﬁned linkage region, we were able to
perform whole-exome sequencing on a single affected family
member. We identiﬁed a total of 1093 variants that were not
present in any public databases or our internal database of
ethnically-matched samples. However, only one of these variants,
c.229C>T, located within exon 4 of the CHST8 gene, was homozy-
gous and located within the autozygous region. This single base
pair transition substitutes an arginine amino acid by a trypto-
phan (R77W). We validated the presence of the homozygous C
to T transition mutation detected by exome sequencing,
c.229C>T, using Sanger sequencing. We PCR ampliﬁed and se-
quenced genomic DNA from individuals 1–18 (Fig. 1A) using
primers speciﬁc for exon 4 and found the c.229C>T mutation,
homozygous in all seven affected family members and heterozy-
gous in carrier individuals, showing complete co-segregation ofFig. 2. GalNAc4-ST1 is expressed throughout normal human epidermis. (A) Immunoﬂuores
against GalNAc4-ST1 reveals expression of this protein throughout the epidermis, most pred
ary between the epidermis and the dermis. (B) Negative control.the mutation with the phenotype. This mutation was excluded
from 400 chromosomes from 200 unrelated healthy control indi-
viduals of Pakistani origin by direct sequencing.
2.4. Immunoﬂuorescence analysis of skin proteins
The CHST8 gene encodes a carbohydrate sulfotransferase, N-
acetylgalactosamine-4-O-sulfotransferase 1 (GalNAc4-ST1). This en-
zyme is a type II transmembrane protein that functions almost exclu-
sively in the Golgi apparatus and transfers sulfate groups to the C4
hydroxyl group of terminal β1,4-linked N-acetylgalactosamine moie-
ties [13]. GalNAc4-ST1 is known to be highly expressed in the pitui-
tary gland, cerebellum and brain and to be required for biosynthesis
of the glycoprotein hormones lutropin and thyrotropin, by mediating
sulfation of their carbohydrate structures. In order to assess whether
GalNAc4-ST1 is expressed in normal human skin, we performed im-
munoﬂuorescence staining of normal human frozen skin sections
with a polyclonal antibody raised against GalNAc4-ST1 (Fig. 2). We
observed expression of GalNAc4-ST1 throughout the epidermis,
with highest expression levels in suprabasal layers (Fig. 2A).
2.5. The missense mutation R77W is predicted to alter amino acid
hydrophilicity
The c.229C>T substitution occurs in exon 4 of CHST8 and results in
a single amino acid substitution, arginine to tryptophan (R77W),
within the Golgi luminal domain of GalNAc4-ST1. The R77 amino
acid is conserved across mammalian species, including human, chim-
panzee, dog, mouse and rat, as depicted in Fig. 3A. Importantly, using
the Swiss-PdbViewer 4.0, we show that the mutation is predicted to
perturb amino acid hydrophilicity due to the substitution of the
basic amino acid arginine to the non-polar amino acid tryptophan
(Fig. 3B). This region of the protein is predicted to be highly hydro-
philic as previously shown in a hydrophilicity plot for GalNAc4-ST1
[14]. These observations suggest that the mutation R77W is likely to
have a detrimental effect on the protein.
2.6. The missense mutation R77W results in decreased expression levels
of full-length protein and loss of protein glycosylation
To study the functional consequences of the R77Wmutation at the
protein level, we cloned both wild type and mutant CHST8 into the
mammalian expression vector pCMV-script and transiently overex-
pressed these constructs in the human HPV16 immortalized keratino-
cyte cell line CCD1106 KERTr. Western blot analysis of whole cellcence staining of normal human frozen skin sections with a polyclonal antibody raised
ominantly in the granular and corniﬁed layers. The dotted white line depicts the bound-
Fig. 3. The c.229C>T (R77W) missense mutation results in decreased expression levels of full-length protein, loss of protein glycosylation and decreased activity of GalNAc4-ST1.
(A) GalNAc4-ST1 protein sequence alignment across species (using HomoloGene, NCBI) shows that R77 is conserved among human, chimpanzee, dog, mouse and rat mammal spe-
cies, but not in chicken or zebra ﬁsh. (B) Amino acid structure and electrostatic potential of GalNAc4-ST1 shows that the mutation perturbs amino acid hydrophilicity. Top panel:
arginine (wild type) and tryptophan (mutant) amino acids are indicated with a red arrow. Blue = N, red = O, white = C, Bottom panel: a change in hydrophilicity due to the sub-
stitution of the basic amino acid arginine (white) by the non-polar amino acid tryptophan (blue) is indicated by the red arrow. Blue = basic amino acid, gray = non-polar amino
acid. Figure generated using the Swiss-PdbViewer 4.0 application of the ExPASy Bioinformatics Resource Portal. (C and D) Western blot of whole cell lysates from CCD1106 kera-
tinocytes transfected with c.229C>T mutant CHST8-pCMVscript (R77W CHST8) shows reduced levels of full length GalNAc4-ST1 (~49 kDa) compared to cells transfected with wild
type CHST8-pCMVscript (WT CHST8). In addition, a lower molecular weight band (~35 kDa) is observed in whole lysates from cells overexpressing mutant CHST8, which is not
detected in cells expressing wild type CHST8 and suggests increased degradation of mutant proteins. Normal keratinocytes (normal CCD1106), non-transfected keratinocytes
that were incubated with Fugene HD only (NT) and cells transfected with empty pCMVscript (vector only) show low levels of full length GalNAc4-ST1. β-actin was used as a control
of equal loading. FL = full length. (D) Lower exposure of blot B clearly showing lower levels of full length GalNAc4-ST1 in cells expressing mutant construct compared to wild type.
(E) Western blot of wild type and mutant recombinant GalNAc4-ST1 proteins before and after treatment with PNGase reveals that, in contrast with wild type proteins, the mutant
proteins are not subject to glycosylation. After PNGase treatment, WT proteins have smaller molecular weight than the untreated ones, but mutant proteins have identical molec-
ular weights before and after treatment. (F) Colorimetric assay for total sulfated GAG quantiﬁcation and comparison between cells transfected with wild type and mutant CHST8
constructs. Decreased levels of total sulfated GAGs are observed in cells expressing mutant GalNAc4-ST1 compared to wild type (n=6), suggesting loss of function of mutant
GalNAc4-ST1 proteins.
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levels of full length GalNAc4-ST1 (~49 kDa), as well as a lower molec-
ular weight (b37 kDa) immunoreactive band in cells transfected with
the mutant CHST8 construct compared to wild type construct (Figs.
3C and D). These results suggest that mutant proteins are subject to
increased degradation. GalNAc4-ST1 contains four potential glycosyl-
ation sites (Figure S2). Since protein glycosylation can protect pro-
teins from degradation, we treated whole lysates from cells
expressing both wild type and mutant recombinant GalNAc4-ST1
with 10% PGNase (an amidase that cleaves nearly all types of N-
glycan chains from glycopeptides/glycoproteins) and performed
western blots. We observed that in cells transfected with wild type
CHST8, recombinant GalNAc4-ST1 is glycosylated, as indicated by
the shift in the molecular weight of this protein upon treatment
with PNGase. In contrast, in cells transfected with mutant CHST8,
the mutant GalNAc4-ST protein was not glycosylated, as shown by
the identical migration of these proteins before and after treatment
with PNGase (Fig. 3E). These results demonstrate that, in contrast
with wild type proteins, the mutant GalNAc4-ST proteins are not sub-
ject to glycosylation, which may result in increased degradation. Dou-
ble immunoﬂuorescence staining of 4% PFA ﬁxed cells with the anti-
CHST8 rabbit polyclonal antibody and a Golgi marker, anti-GM130
mouse monoclonal antibody (BD Biosciences), showed co-
localization of GalNAc4-ST1 with the Golgi apparatus in both wild
type and mutant cells (data not shown).
2.7. The missense mutation R77W results in decreased activity of
GalNAc4-ST1
To test the function of mutant GalNAc4-ST proteins, we used a col-
orimetric assay (Biocolor assay) for the quantiﬁcation of total sulfated
GAGs, in keratinocytes transfected with both wild type and mutant
CHST8 constructs. Decreased levels of total sulfated GAGs were ob-
served in cells expressing mutant GalNAc4-ST1 compared to wild
type proteins, suggesting loss of function of mutant GalNAc4-ST1.
3. Discussion
Mutations in two genes have been associatedwith PSS; TGM5muta-
tions are the underlying cause of the localized form (APPS) and CDSN
mutations lead to type B (inﬂammatory) PSS. However, for the ﬁrst
time, we here describe a mutation in the CHST8 gene, encoding
GalNAc4-ST1, as the underlying cause of type A non-inﬂammatory PSS.
The ﬁrst case of PSS was described by Fox et al. [15] and named as
“keratolysis exfoliativa congenital”. Since then, a number of cases of
PSS have been described, particularly in India, most of which show
characteristics of the type A non-inﬂammatory variant of PSS, which
is otherwise asymptomatic with occasional pruritus. In contrast
with the inﬂammatory type B PSS, type A PSS patients do not show
the presence of vesicles or pustules, fever, sore throat, or involvement
of mucous membrane and nails. Histologically, type A PSS is charac-
terized by a slight hyperkeratosis, thinning of the granular layer and
a separation of the stratum corneum from the underlying stratum
granulosum or an intracorneal split [16]. Cytoplasmic, intracellular
splitting in the lower stratum corneum has also been observed, as
well as abnormal cribriform keratohyalin granules, detected by elec-
tron microscopy, which are indicative of disturbed keratinization. In
some of these patients, reduced desmosomal plaques or intracellular
electron-dense globular deposits within the stratum corneum have
also been observed [4,17,18].
GalNAc4-ST1 is a type II transmembrane protein with 424 amino
acids that harbors four potential N-glycosylation sites and two puta-
tive 3′-phosphoadenosine, 5′-phosphosulfate (PAPS, a ubiquitous sul-
fate donor) binding domains [19] (Figure S2). This protein belongs to
a family of sulphotransferases that includes HNK-1 sulphotransferase
(HNK-1ST, encoded by CHST10), chondroitin-4-sulphotransferases-1-3 (C4ST1-3, encoded by CHST11, CHST12, and CHST13) and
dermatan-4-sulphotransferase-1 (D4ST-1, encoded by CHST14) [13].
GalNAc4-ST1 exhibits 23% sequence homology to HNK-1ST, 28% to
C4ST-1 and 26% to C4ST-2 [14]. Except for HNK-1ST, all the remaining
three enzymes catalyze the transfer of a sulfate group from the PAPS
sulfate donor to carbon-4 of either terminal or non-terminal β-1,4-
linked GalNAc, but GalNAc4-ST1 is speciﬁc for oligosaccharides on
glycoproteins bearing terminal β-1,4-linked GalNAc. Oligosaccharides
terminating with β-1,4-linked GalNAc-4-SO4 have been described on
a limited number of glycoproteins, including carbonic anhydrase VI
(encoded by CA7), tenascin R (encoded by TNR), chondroitin, keratin
sulfate, heparan sulfate and pro-opimelanocortin (POMC) [13], most
of which can be expressed by human keratinocytes. These are poten-
tial substrates for GalNAc4-ST1, but also for some of the other sulpho-
transferases, suggesting some overlap between the different
sulphotransferases.
Here, we identiﬁed a homozygous missense mutation (c.229C>T;
R77W) in the CHST8 gene, encoding GalNAc4-ST1, in a family with
autosomal recessive type A PSS, by using a combination of autozygoz-
ity mapping and whole-exome sequencing. Even though this amino
acid substitution does not occur within a putative PAPS binding site
or glycosylation site of GalNAc4-ST1, we show that it causes reduced
expression levels of full-length GalNAc4-ST1 and that it alters its
overall glycosylation state. In addition to these results, there is further
evidence suggesting that this mutation may result in increased degra-
dation of GalNAc4-ST1; (1) the R77 amino acid is conserved across
mammalian species and resides within a stretch of amino acids that
are highly hydrophilic, (2) the R77W mutation introduces a non-
polar (and hydrophobic) amino acid into this region of the protein,
which is likely to alter the conformation and stability of the protein,
(3) we observe a lower molecular weight peptide in cells transfected
with the mutant CHST8 construct, in addition to lower levels of full-
length protein, compared to cells transfected with wild type CHST8
construct, which suggests that the mutant protein is unstable and
subject to degradation. Therefore, we postulate that the R77W muta-
tion is likely to alter the conformation of the protein leading to reduc-
tion or absence of glycosylation, which may contribute to its
increased turnover rate.
Sulfated groups in glycosaminoglycans and oligosaccharides have
been shown to play crucial roles in conferring highly speciﬁc func-
tions to glycoproteins, glycolipids and proteoglycans, including for
cell–cell interactions, signal transduction and embryonic develop-
ment [20]. Some of these functions include homing of lymphocytes
via interaction of L-selectin with its ligands on the endothelial cells
of high endothelial venule [21,22]; binding of the HNK-1 epitope to
the sulfoglucuronyl sulfoglucuronyl carbohydrate-binding protein,
which plays essential roles in higher brain functions [23,24]; rapid
clearance of a pituitary glycoprotein hormone, lutropin, mediated by
interaction with a hepatic reticulo-endothelial cell receptor [25,26];
myelin function and spermatogenesis mediated by sulfatide and
seminolipid, respectively [27]. In addition, ablation of a speciﬁc sul-
fate group was shown to cause defects in both mouse and drosophila
embryonic development [28,29]. Our observation of substantial
GalNAc4-ST1 protein expression in normal human epidermis, with
increasing levels detected in the upper spinous, granular and corni-
ﬁed layers, suggests that GalNAc4-ST1 plays a role in normal human
epidermal differentiation. Supporting this hypothesis is the fact
that we detected reduced levels of total GAG concentration in cells
expressing mutant GalNAc4-ST1 compared to wild type, indicating
loss of function of the mutant enzyme, which is likely to stem
from its increased turnover rate. These results, coupled with the
phenotype of our patients, which also suggests an abnormal epider-
mal differentiation program, lead us to postulate that GalNAc4-ST1
is important for epidermal homeostasis and that its loss of function
results in increased and continuous desquamation of the stratum
corneum.
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mis has been appreciated for a long time. For instance, cholesterol
sulfate is an important molecule in the epidermis and plays a crucial
role for the cohesion and desquamation of the stratum corneum
[30]. The importance of cholesterol sulfate is underlined by the dis-
covery that loss of steroid sulphatase activity underlies recessive X-
linked ichthyosis [31,32]. In addition, the ability of cultured mouse
and human normal and malignant keratinocytes to synthesize sulfat-
ed GAGs has been demonstrated, including hyaluronic acid, heparan
sulfate and chondroitin sulfate [33,34]. However, the mechanisms of
enzyme activity in these cells have not been elucidated.
In summary, we have identiﬁed a homozygous missense mutation
in the CHST8 gene as the underlying cause of type A non-
inﬂammatory PSS for the ﬁrst time. These ﬁndings emphasize the im-
portance of sulfation of epidermal molecules and, in particular, the
importance of GalNAc4-ST1 for normal epidermal homeostasis. Fur-
ther studies will be required to uncover the substrate(s) in the epi-
dermis that are speciﬁc for GalNAc4-ST1.
4. Materials and methods
4.1. Patients
Informed consent was obtained from all subjects and approval for
this study was provided by the Institutional Review Board of Columbia
University in adherence to the Declaration of Helsinki Principles. Geno-
mic DNAwas isolated fromperipheral blood samples according to stan-
dard techniques [35]. Control skin was obtained from discarded tissue
resulting from routine surgical procedures and processed for immuno-
ﬂuorescence analysis.
4.2. Affymetrix SNP mapping array and linkage
We undertook a genome-wide scan on ten family members using
the low density Affymetrix 10K SNP array. Genespring GT (Agilent
Software) was used for quality control measures and to perform a
number of analyses. SNPs that were not polymorphic or that dis-
played Mendelian inheritance errors were removed, so that the ana-
lyzed dataset contained 7861 SNPs. Haplotypes, or clusters of SNPs
that tend to be inherited together, were inferred from the data by
Genespring GT. Using haplotypes minimizes the effect of linkage dis-
equilibrium on multipoint linkage analysis, reducing type I error. Ini-
tial analysis included genome-wide autozygosity mapping to identify
regions identical by descent that were shared among affected individ-
uals. Details of the methodology used by this test can be found on the
Agilent website. We performed parametric linkage analysis twice,
once using SNP genotypes and once using haplotypes. Microsatellite
markers spanning the region of autozygosity were then used to geno-
type all family members (Fig. 1A).
4.3. Whole-exome sequencing
We performed whole exome sequencing on a single affected fam-
ily member using the SureSelect Human All Exon Kit (Agilent) to cap-
ture the exomes of the affected member. This kit targets
approximately 38 Mb of the genome in a single tube, covering 1.22%
of human genomic regions corresponding to the coding exons. Cap-
tured exons were then subject to paired end sequencing on an Ap-
plied Biosystems SOLiD 4 next generation sequencing system, and
reads were aligned using the Bioscope software for SOLiD.
4.4. Mutation screening
In order to validate our exome-sequencing ﬁndings, we PCR
ampliﬁed exon 4 of the CHST8 gene using primers 5′GTGGTGA-
GAGCCTGACCTGTG and 3′GAGCTGTTGGCCGGGATGGTC. The PCRproducts were directly sequenced in an ABI Prism 310 Automated
Sequencer, with the ABI Prism Big Dye Terminator Cycle Se-
quencing Ready Reaction Kit (PE Applied Biosystems). In addition
to patients and family members, DNA from 200 unrelated healthy
control individuals of Pakistani origin was used to amplify exon 4
of the CHST8 gene, and the resulting DNA fragments were se-
quenced directly.
4.5. Immunoﬂuorescence staining
Normal skin cryosections (8-μm thick) were ﬁxed in 4% parafor-
maldehyde (PFA, Sigma) for 15 min and blocked in 5% goat serum
for 40 min, followed by incubation overnight at 4 °C with an anti-
CHST8 rabbit polyclonal antibody (1:200 dilution, HPA016004,
Sigma Prestige). Incubation with Alexa Fluor 488- (green) conjugated
goat anti-rabbit IgG secondary antibody (1:800 dilution, Invitrogen)
was then performed for 40 min at room temperature. Sections were
mounted with DAPI-containing VECTASHIELD Mounting Medium
(Vector Laboratories). Primary antibody was omitted from the nega-
tive control. Immunoﬂuorescent images were acquired with a Zeiss
LSM 510 laser scanning confocal microscope (Carl Zeiss).
4.6. Recombinant GalNAc4-ST1 expression
We cloned both wild type and mutant CHST8 into the mammalian
expression vector pCMV-script (Addgene). To accomplish this,
human fetal brain cDNA (Clontech) was PCR ampliﬁed using the
CHST8-speciﬁc primers 5′ CGCGAATTCGATGACCCTGCGACCTGGAA
CAATG and 3′ CAGAAGCTTTCAGAGCCCTGTTGCTCCCAGGAT. The PCR
cycling conditions were 94 °C for 2 min followed by 35 cycles of
94 °C for 30 s, 55 °C for 30 s and 68 °C for 1.5 min, with a ﬁnal exten-
sion step of 5 min at 68 °C. The PCR products were directly cloned into
the pCR™4-TOPO® TA vector, using the TOPO® TA Cloning® Kit
(Invitrogen) and fully sequenced to conﬁrm that the correct CHST8
sequence was cloned. To generate the c.229C>T mutation, site direct-
ed mutagenesis was performed using the QuikChange II XL Site-
Directed Mutagenesis Kit (Agilent Technologies), and the primers
used were 5′ CCACAGAGAGGGTCACTTGGGACTTATCCAGTGGG and
3′ CCCACTGGATAAGTCCCAAGTGACCCTCTCTGTGG. Following conﬁr-
mation of the correct sequence by sequencing analysis, wild type
and mutant cDNA clones were subcloned into the pCMVscript mam-
malian expression vector using the EcoRI and HindIII restriction en-
zymes (NEB). We transiently overexpressed these constructs, using
Fugene HD (Promega) transfections, in the human HPV16 immortal-
ized keratinocyte cell line CCD1106 KERTr, under culture conditions
speciﬁed by the manufacturer (ATCC, CRL-2309).
4.7. Immunoblotting
Whole-cell protein extracts were prepared from cells lysed in
0.125 M Tris–HCl pH 6.8, 4% (w/v) SDS, 20% (v/v) glycerol, 0.001%
(w/v) bromophenol and 1.44 M β-mercaptoethanol, boiled for
5 min and resolved on 12% Mini-PROTEAN® TGX™ Precast Gel
(Biorad) according to the manufacturer's instructions. The primary
antibody used was the anti-CHST8 rabbit polyclonal antibody
(HPA016004, Sigma Prestige). To determine the glycosylation state
of both wild type and mutant recombinant GalNAc4-ST1, whole ly-
sates from cells expressing wild type and mutant constructs were
treated with 10% PGNase according to the manufacturer's instructions
(New England Biolabs), prior to western blotting.
4.8. Biocolor assay
A colorimetric assay for quantiﬁcation of total sulfated GAGs was
performed. Keratinocytes were ﬁrst lysed in 400 μl of K2HPO4 100 mM
pH8.0, Triton X-100 0.5% buffer. A 100 μl-aliquotwas used to determine
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Scientiﬁc), and the remaining 300 μl of protein lysate were digested
with proteinase K (50 μg/ml ﬁnal concentration) at 56 °C for 12 h.
Heat inactivation of the enzyme was carried out at 90 °C for 10 min
and the mixture was centrifuged (10,000×g, 10 min) through an ultra-
free 0.22 μm ﬁlter (Millipore). Sulfated GAG quantiﬁcation was per-
formed according to the procedure previously published by Barbosa et
al [36]. Brieﬂy, 1 ml of DMMB solutionwas added to adjusted-100 μl-al-
iquots of digested samples and shaken for 30 min. Following centrifuga-
tion at 12,000×g for 10 min, the supernatant was discarded and 1 ml of
decomplexation solution (4 M guanidine hydrochloride in 10% propan-
1-ol and acetate tri-hydrate buffer 50 mMpH6.8)was added to the pre-
cipitate. The mixture was shaken for 30 min and its absorbance at
655 nm was measured. The sulfated GAG concentration was deter-
mined by comparison with a chondroitin sulfate calibration curve.
4.9. Protein sequence alignment and in silico modeling
GalNAc4-ST1 protein sequence alignment across species was per-
formed using HomoloGene, NCBI. In silico modeling of amino acid
structure and electrostatic potential of GalNAc4-ST1 was performed
using the Swiss-PdbViewer 4.0 application of the ExPASy Bioinfor-
matics Resource Portal.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.ygeno.2012.01.005.
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